{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["McKenna MK"],"funding":["NIAID NIH HHS","NHLBI NIH HHS","National Cancer Institute","NCI NIH HHS","National Institutes of Health","Cancer Prevention and Research Institute of Texas","NIGMS NIH HHS"],"pagination":["e005891"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9853244"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(1)"],"pubmed_abstract":["<h4>Background</h4>Cell therapies for solid tumors are thwarted by the hostile tumor microenvironment (TME) and by heterogeneous expression of tumor target antigens. We address both limitations with a novel class of chimeric antigen receptors based on plant lectins, which recognize the aberrant sugar residues that are a 'hallmark' of both malignant and associated stromal cells. We have expressed in T cells a modified lectin from banana, H84T BanLec, attached to a chimeric antigen receptor (H84T-CAR) that recognizes high-mannose (asparagine residue with five to nine mannoses). Here, we tested the efficacy of our novel H84T CAR in models of pancreatic ductal adenocarcinoma (PDAC), intractable tumors with aberrant glycosylation and characterized by desmoplastic stroma largely contributed by p"],"journal":["Journal for immunotherapy of cancer"],"pubmed_title":["Novel banana lectin CAR-T cells to target pancreatic tumors and tumor-associated stroma."],"pmcid":["PMC9853244"],"funding_grant_id":["P01 CA094237","R24 GM137763","5T32HL092332-17","RP220666","P50 CA126752","5PO1CA094237-15","T32 HL092332","R01 AI175124","P30 CA125123"],"pubmed_authors":["Markovitz DM","Thomas DG","Brenner D","McKenna MK","Ashwood C","Watanabe N","Brenner MK","Ozcan A","Legendre M","Cummings RD","Bonifant C"],"additional_accession":[]},"is_claimable":false,"name":"Novel banana lectin CAR-T cells to target pancreatic tumors and tumor-associated stroma.","description":"<h4>Background</h4>Cell therapies for solid tumors are thwarted by the hostile tumor microenvironment (TME) and by heterogeneous expression of tumor target antigens. We address both limitations with a novel class of chimeric antigen receptors based on plant lectins, which recognize the aberrant sugar residues that are a 'hallmark' of both malignant and associated stromal cells. We have expressed in T cells a modified lectin from banana, H84T BanLec, attached to a chimeric antigen receptor (H84T-CAR) that recognizes high-mannose (asparagine residue with five to nine mannoses). Here, we tested the efficacy of our novel H84T CAR in models of pancreatic ductal adenocarcinoma (PDAC), intractable tumors with aberrant glycosylation and characterized by desmoplastic stroma largely contributed by p","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jan","modification":"2026-05-04T18:48:42.624Z","creation":"2026-04-07T20:47:54.015Z"},"accession":"S-EPMC9853244","cross_references":{"pubmed":["36653070"],"doi":["10.1136/jitc-2022-005891"]}}